Literature DB >> 20434552

Vaccination with multimeric L2 fusion protein and L1 VLP or capsomeres to broaden protection against HPV infection.

Subhashini Jagu1, Kihyuck Kwak, Robert L Garcea, Richard B S Roden.   

Abstract

Immunization with L1 as pentavalent capsomeres or virus-like particles (VLPs) generates high and long-lived titers of neutralizing antibodies and protection primarily against the human papillomavirus (HPV) type from which the vaccine was derived. Conversely, vaccination with L2 minor capsid protein derived from multiple HPV types induces lower titer, but more broadly neutralizing and protective antibody responses. We combined the advantages of each protective antigen by immunization with titrated doses of multi-type L2 with either L1 capsomeres or VLP. We observed no significant interference between the L1 and L2 antibody response upon co-administration of L1 vaccines with multi-type L2 vaccines. 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20434552      PMCID: PMC2918737          DOI: 10.1016/j.vaccine.2010.04.039

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  47 in total

1.  Papillomavirus capsid protein expression in Escherichia coli: purification and assembly of HPV11 and HPV16 L1.

Authors:  X S Chen; G Casini; S C Harrison; R L Garcea
Journal:  J Mol Biol       Date:  2001-03-16       Impact factor: 5.469

2.  Papillomavirus-like particles induce acute activation of dendritic cells.

Authors:  P Lenz; P M Day; Y Y Pang; S A Frye; P N Jensen; D R Lowy; J T Schiller
Journal:  J Immunol       Date:  2001-05-01       Impact factor: 5.422

3.  Minor capsid protein of human genital papillomaviruses contains subdominant, cross-neutralizing epitopes.

Authors:  R B Roden; W H Yutzy; R Fallon; S Inglis; D R Lowy; J T Schiller
Journal:  Virology       Date:  2000-05-10       Impact factor: 3.616

4.  Immunization with a pentameric L1 fusion protein protects against papillomavirus infection.

Authors:  H Yuan; P A Estes; Y Chen; J Newsome; V A Olcese; R L Garcea; R Schlegel
Journal:  J Virol       Date:  2001-09       Impact factor: 5.103

5.  Structure of small virus-like particles assembled from the L1 protein of human papillomavirus 16.

Authors:  X S Chen; R L Garcea; I Goldberg; G Casini; S C Harrison
Journal:  Mol Cell       Date:  2000-03       Impact factor: 17.970

6.  Protective immunity to rabbit oral and cutaneous papillomaviruses by immunization with short peptides of L2, the minor capsid protein.

Authors:  Monica E Embers; Lynn R Budgeon; Martin Pickel; Neil D Christensen
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

7.  Analysis of modified human papillomavirus type 16 L1 capsomeres: the ability to assemble into larger particles correlates with higher immunogenicity.

Authors:  Lysann Schädlich; Tilo Senger; Britta Gerlach; Norbert Mücke; Corinna Klein; Ignacio G Bravo; Martin Müller; Lutz Gissmann
Journal:  J Virol       Date:  2009-05-20       Impact factor: 5.103

8.  Comparison of the immunogenicity and safety of Cervarix and Gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years.

Authors:  Mark H Einstein; Mira Baron; Myron J Levin; Archana Chatterjee; Robert P Edwards; Fred Zepp; Isabelle Carletti; Francis J Dessy; Andrew F Trofa; Anne Schuind; Gary Dubin
Journal:  Hum Vaccin       Date:  2009-10-14

9.  Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women.

Authors:  J Paavonen; P Naud; J Salmerón; C M Wheeler; S-N Chow; D Apter; H Kitchener; X Castellsague; J C Teixeira; S R Skinner; J Hedrick; U Jaisamrarn; G Limson; S Garland; A Szarewski; B Romanowski; F Y Aoki; T F Schwarz; W A J Poppe; F X Bosch; D Jenkins; K Hardt; T Zahaf; D Descamps; F Struyf; M Lehtinen; G Dubin
Journal:  Lancet       Date:  2009-07-06       Impact factor: 79.321

10.  Concatenated multitype L2 fusion proteins as candidate prophylactic pan-human papillomavirus vaccines.

Authors:  Subhashini Jagu; Balasubramanyam Karanam; Ratish Gambhira; Sudha V Chivukula; Revathi J Chaganti; Douglas R Lowy; John T Schiller; Richard B S Roden
Journal:  J Natl Cancer Inst       Date:  2009-05-26       Impact factor: 13.506

View more
  27 in total

Review 1.  Prevention of cancer by prophylactic human papillomavirus vaccines.

Authors:  Kihyuck Kwak; Anna Yemelyanova; Richard B S Roden
Journal:  Curr Opin Immunol       Date:  2010-12-23       Impact factor: 7.486

2.  Branched-linear and agglomerate protein polymers as vaccine platforms.

Authors:  Leyi Wang; Ming Xia; Pengwei Huang; Hao Fang; Dianjun Cao; Xiang-Jin Meng; Monica McNeal; Xi Jiang; Ming Tan
Journal:  Biomaterials       Date:  2014-06-28       Impact factor: 12.479

3.  Structural constraints on the three-dimensional geometry of simple viruses: case studies of a new predictive tool.

Authors:  Thomas Keef; Jessica P Wardman; Neil A Ranson; Peter G Stockley; Reidun Twarock
Journal:  Acta Crystallogr A       Date:  2013-01-08       Impact factor: 2.290

Review 4.  Virus-like particles for the prevention of human papillomavirus-associated malignancies.

Authors:  Joshua W Wang; Richard B S Roden
Journal:  Expert Rev Vaccines       Date:  2013-02       Impact factor: 5.217

5.  Development of a highly thermostable, adjuvanted human papillomavirus vaccine.

Authors:  Kimberly J Hassett; Natalie M Meinerz; Florian Semmelmann; Megan C Cousins; Robert L Garcea; Theodore W Randolph
Journal:  Eur J Pharm Biopharm       Date:  2015-05-18       Impact factor: 5.571

6.  Glassy-state stabilization of a dominant negative inhibitor anthrax vaccine containing aluminum hydroxide and glycopyranoside lipid A adjuvants.

Authors:  Kimberly J Hassett; David J Vance; Nishant K Jain; Neha Sahni; Lilia A Rabia; Megan C Cousins; Sangeeta Joshi; David B Volkin; C Russell Middaugh; Nicholas J Mantis; John F Carpenter; Theodore W Randolph
Journal:  J Pharm Sci       Date:  2015-01-11       Impact factor: 3.534

7.  Design strategies to address the effect of hydrophobic epitope on stability and in vitro assembly of modular virus-like particle.

Authors:  Alemu Tekewe; Natalie K Connors; Anton P J Middelberg; Linda H L Lua
Journal:  Protein Sci       Date:  2016-06-13       Impact factor: 6.725

Review 8.  Second-generation prophylactic HPV vaccines: successes and challenges.

Authors:  Mitchell Tyler; Ebenezer Tumban; Bryce Chackerian
Journal:  Expert Rev Vaccines       Date:  2013-12-18       Impact factor: 5.217

Review 9.  Emerging human papillomavirus vaccines.

Authors:  Barbara Ma; Bharat Maraj; Nam Phuong Tran; Jayne Knoff; Alexander Chen; Ronald D Alvarez; Chien-Fu Hung; T-C Wu
Journal:  Expert Opin Emerg Drugs       Date:  2012-11-19       Impact factor: 4.191

Review 10.  New approaches to prophylactic human papillomavirus vaccines for cervical cancer prevention.

Authors:  Elizabeth D Gersch; Lutz Gissmann; Robert L Garcea
Journal:  Antivir Ther       Date:  2011-11-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.